drugset / Trial / NCT04998487
A Single-Dose Study of LY3471851 in Healthy Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The main purpose of this study is to estimate how much LY3471851 gets into the blood stream and how long it takes the body to remove it when administered under the skin in healthy participants. The study will also evaluate the safety and tolerability of LY3471851. The study is expected to last up to 87 days for each participant.
Timeline
- Start
- 2021-08-16
- Primary completion
- 2022-07-06
- Completion
- 2022-07-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rezpegaldesleukin | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.